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Abstract
Nasopharyngeal carcinoma (NPC) is closely associated with Epstein–Barr virus (EBV) infection. The EBV-encoded
latent membrane protein 1 (LMP1), which is commonly expressed in NPC, engages multiple signaling pathways
that promote cell growth, transformation, and metabolic reprogramming. Here, we report a novel function of
LMP1 in promoting de novo lipogenesis. LMP1 increases the expression, maturation and activation of sterol
regulatory element-binding protein 1 (SREBP1), a master regulator of lipogenesis, and its downstream target
fatty acid synthase (FASN). LMP1 also induces de novo lipid synthesis and lipid droplet formation. In contrast,
small interfering RNA (siRNA) knockdown of LMP1 in EBV-infected epithelial cells diminished SREBP1 activation
and lipid biosynthesis. Furthermore, inhibition of the mammalian target of rapamycin (mTOR) pathway, through
the use of either mTOR inhibitors or siRNAs, significantly reduced LMP1-mediated SREBP1 activity and lipogenesis,
indicating that LMP1 activation of the mTOR pathway is required for SREBP1-mediated lipogenesis. In primary NPC
tumors, FASN overexpression is common, with high levels correlating significantly with LMP1 expression. Moreover,
elevated FASN expression was associated with aggressive disease and poor survival in NPC patients. Luteolin and
fatostatin, two inhibitors of lipogenesis, suppressed lipogenesis and proliferation of nasopharyngeal epithelial cells,
effects that were more profound in cells expressing LMP1. Luteolin and fatostatin also dramatically inhibited NPC
tumor growth in vitro and in vivo. Our findings demonstrate that LMP1 activation of SREBP1-mediated lipogenesis
promotes tumor cell growth and is involved in EBV-driven NPC pathogenesis. Our results also reveal the therapeutic
potential of utilizing lipogenesis inhibitors in the treatment of locally advanced or metastatic NPC.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Non-keratinizing undifferentiated nasopharyngeal
carcinoma (NPC) is a distinct type of cancer that is
prevalent in Southeast Asia and southern China. The
unique feature of NPC is its strong association with
Epstein–Barr virus (EBV) infection [1,2]. Among the
EBV-encoded gene products expressed in NPC, latent
membrane protein 1 (LMP1) is of particular interest, as
it shows oncogenic properties in vitro and in vivo. LMP1
is an integral membrane protein containing two signal-
ing domains: CTAR1 and CTAR2. Through these two
domains, LMP1 engages multiple signaling cascades
that include the Ras–extracellular signal-regulated
kinase (ERK)–mitogen-activated protein kinase
(MAPK), phosphoinositide 3-kinase (PI3K)–AKT,
nuclear factor-κB (NF-κB) and p38-MAPK pathways,
which modulate the expression of a variety of cellular
targets that contribute to the transforming activities of
LMP1 [1–3]. Previous studies have established a role
for LMP1 in promoting cell proliferation, transforma-
tion, cell invasion and migration, aerobic glycolysis and
metabolic reprogramming in nasopharyngeal epithelial
cells [3–5]. These observations imply an essential role
for LMP1 in the pathogenesis of NPC.
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This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any
medium, provided the original work is properly cited.
Activation of SREBP1-mediated lipogenesis by EBV-encoded LMP1 181
Deregulated lipid metabolism is an established hall-
mark of cancer. Cells obtain fatty acids either from the
diet or through de novo lipid synthesis (lipogenesis).
Normal cells rely primarily on dietary fatty acid for the
synthesis of new structural lipids, and lipogenesis is not
universal. However, cancer cells extensively engage de
novo lipogenesis to produce long-chain fatty acids that
are essential for the synthesis of glycerophospholipid
membrane and membrane signal molecules during rapid
cell proliferation (supplementary material, Figure S5).
Fatty acids are also necessary for energy storage as
lipid droplets [6–8]. Lipogenesis is tightly regulated
by sterol regulatory element-binding protein (SREBP)
1, a transcription factor that regulates the transcription
of most genes involved in lipogenesis [9–11]. There
are two SREBP1 isoforms (SREBP1a and SREBP1c)
encoded by SREBF1. SREBF1a and SREBF1c are
produced from different promoters, differing only in
the lengths of their N-terminal transactivation domains.
SREBPs are synthesized as precursor proteins bound
to the endoplasmic reticulum (ER) membrane. After
stimulation, the SREBP precursor undergoes proteolytic
cleavage in the Golgi to release the transcriptionally
active N-terminal domain. Once mature, active SREBP1
translocates to the nucleus, where it binds to sterol reg-
ulatory elements (SREs) within its promoter and its
target genes [9–11]. Mammalian target of rapamycin
(mTOR) complex 1 (mTORC1) and mTOR complex
2 (mTORC2) have been shown to regulate SREBP1
activity and lipogenesis. Activation of mTOR signaling
by the Ras–ERK and PI3K–AKT pathways increases
expression of SREBPs and SREBP-mediated lipogene-
sis [12–14]. Numerous lipogenic genes, including that
encoding fatty acid synthase (FASN), are upregulated in
a variety of cancers [7,8,10]. In this study, we demon-
strate that FASN expression is common in primary
NPC tumors, with higher levels correlating with LMP1
expression. Furthermore, LMP1 activates de novo lipo-
genesis, and LMP1 activation of SREBP1-mediated
lipogenesis contributes to cancer cell growth and tumor
progression. These findings imply the involvement of
LMP1-mediated lipogenesis in the pathogenesis of
EBV-infected NPC.
Materials and methods
Cell lines, chemicals, and pharmacological inhibitors
C666-1 and HK-1 NPC cell lines were maintained
in RPMI-1640 medium supplemented with 10%
fetal bovine serum. The SV40 large T-immortalized
nasopharyngeal epithelial cell line NP69 was main-
tained in keratinocyte serum-free medium (Thermo
Fisher Scientific, Waltham, MA, USA). Torin 1, Torin
2, luteolin and fatostatin were obtained from Abcam
(Cambridge, UK). Further details are presented in
supplementary material, Supplementary materials
and methods.
DNA constructs and small interfering RNA (siRNA)
Scrambled short hairpin RNA (shRNA) and LMP1
shRNA vectors were generated by inserting a
fragment of synthesized oligonucleotide with a
scrambled sequence or a sequence for LMP1 into
pSUPER.retro.puro vector (OligoEngine, Seattle, WA,
USA). The pGL2-3xSRE luciferase vector was obtained
from ATCC (Manassas, VA, USA). pGL3-FASN
was kindly provided by Qiang Liu (University of
Saskatchewan, Saskatoon, Canada) [15]. All siRNAs
were purchased fromDharmacon (Lafayette, CO, USA).
Transient transfection of siRNA and DNA was per-
formed with Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) and Fugene HD (Promega, Madison, WI,
USA) respectively. See supplementary material, Supple-
mentary materials and methods, for additional details.
Western blotting analysis
Total cell lysates (5–50 μg of protein) were separated by
10% or 4–12% sodium dodecylsulfate polyacrylamide
gel electrophoresis, and transferred to poly(vinylidene
difluoride) membranes prior to immunoblotting. Anti-
bodies against LMP1 (clones CS1-4; 1:1000 dilution)
were purchased from Dako (Glostrup, Denmark), and
antibodies against α-tubulin (Cat. No. sc-8035; 1:5000
dilution) were purchased from Santa Cruz (Dallas, TX,
USA). The anti-SREBP1 antibody (2A4; 1:1000 dilu-
tion) was purchased from Abcam and Santa Cruz. All
other antibodies were purchased from Cell Signaling
Technology (Beverley, MA, USA). Additional details
are provided in supplementary material, Supplementary
materials and methods.
Reverse transcription quantitative polymerase chain
reaction (RT-qPCR)
All RT-qPCR products were amplified with the Power
SYBR green PCR Master Mix Kit (Thermo Fisher Sci-
entific). Details, including primer sequences, are pro-
vided in supplementary material, Supplementary mate-
rials and methods.
Luciferase reporter assay
Ten thousand HeLa or HEK-293 cells grown in 96-well
plates were co-transfected with 20 ng of the luciferase
reporter construct together with increasing amounts of
an LMP1 expression vector (pCDNA3-LMP1), as indi-
cated in Figure 1. Renilla pRL-SV40 vector was trans-
fected as an internal control to correct for transfection
efficiency. Two days after transfection, cells were lysed
in reporter lysis buffer, and then assayed for firefly and
Renilla luciferase activities with the Dual-Luciferase
Reporter Assay System (Promega).
Immunofluorescence staining
Immunofluorescence staining was performed as previ-
ously described [16] and as further outlined in supple-
mentary material, Supplementary materials and meth-
ods.
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Lipid droplet fluorescence staining
Nile Red fluorescence staining was assessed with the
Lipid Droplets Fluorescence Assay Kit according to
the manufacturer’s protocol (Cayman Chemical, Ann
Arbor, MI, USA). Details are provided in supplementary
material, Supplementary materials and methods.
Immunohistochemical staining
Immunohistochemical staining was performed as
described previously [17]. Information regarding
normal and tumor specimens, staining and intensity
score methods are outlined in supplementary material,
Supplementary materials and methods.
Cell proliferation assay
Cell proliferation assays were performed with cell
proliferation reagent CCK-8 (Dojindo Molecular Tech-
nologies, Rockville, MD, USA) and as described in
supplementary material, Supplementary materials and
methods.
De novo lipogenesis assay
For the lipogenesis assay, cells were incubated
in serum-free medium containing 2.5 μCi/ml
[1-14C]acetate for 8–12 h. After being washed with
phosphate-buffered saline (PBS), cells were lysed in
0.5% Triton X-100/PBS. Lipids were extracted by
successive addition of methanol and chloroform, fol-
lowed by centrifugation at 16,000× g for 15 minutes.
The organic phase was air-dried and resuspended in
chloroform for scintillation counting. Results were
normalized to total protein content. Details are provided
in supplementary material, Supplementary materials
and methods.
In vivo tumorigenicity experiments
The University Animal Experimentation Ethics Com-
mittee of the Chinese University of Hong Kong
approved the study protocol. In brief, C666-1 cells
(1× 107) were inoculated subcutaneously into BALB/c
nude mice. When the size of tumors reached 50mm3,
mice were injected intravenously with PBS (vehicle),
luteolin or fatostatin every 2–3 days for 3weeks. At
the endpoint, mice were killed and tumors were har-
vested. For further details, see supplementary material,
Supplementary materials and methods.
Statistical analysis
Statistical analyses were performed with GraphPad
Prism 5.0 (GraphPad Software, La Jolla, CA, USA). P
values were calculated with either Fisher’s exact test
or an unpaired two-tailed Student’s t-test. The IC50
values of inhibitors were calculated by applying the
four-parameter logistic equation to generate the sig-
moidal dose–response (variable slope) curves. Survival
curves were analyzed with the Kaplan–Meier method,
and were compared by use of a log-rank test. A P value
of <0.05 was considered to be statistically significant.
Results
LMP1 increases SREBP1 expression and activity
To examine the impact of LMP1 on SREBP1-mediated
lipogenesis, increasing amounts of an LMP1 expression
vector were transfected into the nasopharyngeal epithe-
lial cell line NP69. Under serum-deprived conditions,
dose-dependent induction of SREBF1a and SREBF1c
mRNA was observed (Figure 1A). Similarly, LMP1
increased the levels of both precursor and mature forms
of SREBP1 protein (Figure 1C). SREBP1 transactivates
target genes by binding to SREs within the promoter
region. Using a pGL2-3xSRE reporter construct con-
taining three tandem copies of an SRE/SP1 element
[18], we found that LMP1 increased SREBP1 tran-
scriptional activity (Figure 1B). FASN is a transcrip-
tional target of SREBP1. FASN promoter activity was
also strongly enhanced in response to LMP1 expression
(Figure 1B). The expression of FASN mRNA and the
expression of FASN protein were also induced by LMP1
(Figure 1A,C). These findings suggest that FASN induc-
tion by LMP1 is mediated primarily through modulation
of the expression and activity of SREBP1. ThemTORC1
and mTORC2 pathways are both involved in regulating
SREBP1 activity [12–14]. LMP1 has been reported to
activate themTOR signaling pathway [18–20]. Here, we
provided further evidence that LMP1 induces phospho-
rylation of 4E-BP1 and p70S6K, two established down-
stream targets of mTOR signaling (Figure 1C).
In nasopharyngeal epithelial cells stably express-
ing LMP1, we also observed increased activities of the
SREBP1 andmTOR pathways (Figure 1D). Immunoflu-
orescence staining revealed overexpression of FASN
in LMP1-expressing nasopharyngeal epithelial cells
(Figure 1E). To determine whether LMP1 promotes de
novo lipogenesis, LMP1-expressing cells were labeled
with [14C]acetate for 8–12 h under serum-deprived
conditions. The 14C-labeled lipid fraction was then
extracted for quantification. As shown in Figure 1F,
LMP1-expressing cells produced more newly synthe-
sized lipid than control cells. Furthermore, Nile Red
staining revealed more intracellular lipid droplets in
LMP1-expressing cells (Figure 1G,H). Overall, these
data indicate a role for LMP1 in promoting lipid
biosynthesis.
LMP1 promotes SREBP1-mediated lipogenesis
in EBV-infected NPC cells
In NPC xenografts (C17, X2117, and C15), western
blotting analysis revealed higher levels of the precur-
sor and mature forms of SREBP1 and FASN in the
LMP1-positive X2117 and C15 xenografts than in
the LMP1-negative C17 xenograft and EBV-negative
non-malignant NP69 nasopharyngeal epithelial cell
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Figure 1. Induction of SREBP1 expression and activity by LMP1. (A) NP69 cells transfected with increasing amounts of an LMP1 expression
vector as indicated were subjected to RT-qPCR analysis for SREBF1a, SREBF1c, LMP1, and FASN. The mRNA expression of the target gene
of interest was normalized to expression of TBP . Relative mRNA levels were calculated with the sample without the LMP1 expression vector
(set at 1). (B) HEK-293 cells were transfected with various amounts of an LMP1 expression vector together with luciferase promoter vector:
pGL2-3xSRE or pGL3-FASN. After serum deprivation for 12 h, cells were harvested for reporter activity analysis. The firefly luciferase activity
was normalized to Renilla luciferase activity, and plotted relative to the sample without the LMP1 expression vector (set at 1). (C and D)
NP69 cells transfected with increasing amounts of an LMP1 expression vector as indicated (C) or NP69 and HK1 cells stably expressing
LMP1 (D) were incubated in serum-free medium for 12 h, prior to immunoblotting analysis. (E) Immunofluorescence staining of FASN. (F)
[14C]Acetate incorporation assay for the measurement of de novo lipid synthesis. (G) Nile Red fluorescence staining for lipid droplets and
counterstaining with Hoechst 33342 to stain cell nuclei. As a positive control for lipid droplet staining (right panel), pLNSX control cells
were incubated in medium supplemented with oleic acid for 12 h prior to staining. Nile Red fluorescence (excitation, 385 nm; emission,
535 nm) and Hoechst 33342 fluorescence (excitation, 355 nm; emission, 460 nm). (H) The relative amount of lipid droplet formation was
calculated by normalizing the Hoechst 33342 fluorescence to the Nile Red signal in each well, and compared with the pLNSX vector control
sample (set at 1). Data represent the means of eight determinations. Mean and standard deviation. ***p< 0.001.
line (Figure 2A). In NPC cell lines, the levels of
mature SREBP1 and FASN proteins were higher
in EBV-infected HK1-EBV and C666-1 cells than
in HK-1 cells (Figure 2B). Similarly, levels of the
phosphorylated forms of 4E-BP1 and p70S6K were
elevated in HK1-EBV and C666-1 cells (Figure 2B).
A role for LMP1 in these effects was established,
as siRNA silencing of LMP1 in EBV-infected cells
resulted in reductions in the expression levels of mature
SREBP1 and FASN, as well as a reduction in the
signaling activity of mTOR (Figure 2C). Further-
more, LMP1 silencing in C666-1 cells resulted in a
decrease in FASN promoter activity (supplementary
material, Figure S1) as well as lipogenesis, particularly
under serum-deprived condition (Figure 2D). These
data suggest that SREPB1-mediated lipogenesis in
EBV-infected cells is induced by LMP1 through the
mTOR signaling pathway.
LMP1 induces SREBP1-mediated lipogenesis
through the mTOR signaling pathway
To investigate whether LMP1-induced lipogenesis
was dependent on mTOR signaling, NP69-pLNSX
and NP69-LMP1 cells were treated with the mTOR
inhibitors Torin 1 and Torin 2. Torin 1 has been shown
to inhibit both mTORC1 and mTORC2 complexes,
whereas Torin 2 inhibits the mTORC1 complex [21,22].
[14C]Acetate incorporation assays revealed that these
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Figure 2. LMP1 induction of SREBP1-mediated lipogenesis in EBV-infected NPC cells. (A) NPC xenografts (C17, 2117, and C15) together
with cells of the immortalized nasopharyngeal epithelial cell line, NP69, which were incubated in serum-free medium for 16 h prior to
harvesting, were subjected to western blotting analysis for the indicated proteins. (B) The EBV-infected NPC cell lines HK1-EBV and C666-1,
together with EBV-negative HK-1 cells, were incubated in serum-free medium for 12 h prior to western blotting analysis. (C) HK1-EBV and
C666-1 cells transfected with negative siRNA control (si-Control) or siRNA targeting LMP1 (si-LMP1) were subjected to western blotting
analysis. (D) C666-1 cells expressing pSuper.retro-shRNA scrambled control (ShC) or shRNA LMP1 (ShLMP1) were incubated in serum-rich
(SR) or serum-free (SF) medium containing 2.5 μCi/ml [1-14C]acetate for 10 h, and then subjected to measurement of lipid synthesis. NS*,
non-specific band. Mean and standard deviation. ***p< 0.001.
two mTOR inhibitors could suppress lipogenesis in
both cell lines, although the effects were more profound
in LMP1-expressing cells. As shown in Figure 3A,
NP69-LMP1 cells showed a 53–72% reduction in
lipogenesis, whereas only a 15–39% reduction was
observed in NP69-pLNSX cells. To further investi-
gate whether LMP1 induction of mTOR signaling
promoted SREBP1-mediated lipogenesis, NP69 cells
were transiently transfected with an LMP1 expression
vector together with siRNAs targeting raptor to inhibit
mTORC1 signaling, rictor to inhibit mTORC2 signal-
ing, or mTOR to inhibit both mTORC1 and mTORC2
signaling. As shown in Figure 3B, inhibition of either
mTORC1, mTORC2 or both reduced LMP1-induced
FASN expression and SREBP1 maturation. Also,
NP69-LMP1 cells showed a 20–35% reduction in
lipogenesis, whereas a 14–27% reduction was observed
in control NP69-pLNSX cells (Figure 3C). These
findings indicated that mTOR signaling contributes to
LMP1-induced lipogenesis.
Expression of FASN correlates with LMP1 expression
in NPCs and poor prognosis in NPC patients
To examine the expression of FASN in NPC, we per-
formed immunohistochemical staining for FASN and
LMP1 in 38 NPC primary tumors. The intensity of
FASN staining was scored, and a graph of the statistical
dot-plot of FASN staining intensity against LMP1
expression was generated (Figure 4B). Immunohisto-
chemical staining revealed absent or low expression
of FASN (immunoreactivity score of <3) in normal
nasopharyngeal epithelium (Figure 4A, N1), and 16
of 38 (42%) NPC tumors in which LMP1 expression
was barely detectable (Figure 4A, representative NPC:
T4). In contrast, moderate or high levels of FASN
(immunoreactivity score of ≥3) were observed in 22 of
38 NPC tumors (58%) (Figure 5A, representative NPC:
T13, T22, and T34). In particular, LMP1-positive tumors
showed significantly higher levels of FASN (p= 0.0003)
(Figure 4B). In analysis of FASN expression with clin-
icopathological variables including gender, age, tumor
size, lymph node and cancer stage in NPC patients,
we found that higher levels of FASN expression (score
of ≥3) significantly correlated with advanced primary
tumor (T3–T4; p= 0.012) and distant lymph node
metastasis (N1–N3; p= 0.005) of NPC (supplemen-
tary material, Table S1). Also, Kaplan–Meier survival
analysis revealed that elevated FASN expression sig-
nificantly correlated with poor survival (p= 0.02)
(Figure 4C). Overall, these findings indicate that FASN
overexpression is common in NPC and is correlated
with LMP1 expression. Moreover, the elevated FASN
expression is associated with aggressive disease and
poor prognosis in NPC patients. These also imply a role
of LMP1 in upregulating FASN for NPC progression.
LMP1 induction of lipid synthesis contributes to cell
growth
Next, we examined whether LMP1 induction of lipo-
genesis contributed to cell growth. NP69 and HK1
cells expressing pLNSX control or LMP1 were treated
with luteolin or fatostatin. Luteolin is an inhibitor that
suppresses SREBP-mediated lipogenesis. Fatostatin
is an SREBP-specific inhibitor [23–25]. [14C]Acetate
incorporation assays revealed that these inhibitors
could dampen lipogenesis in all cell lines; however, the
repression was more evident in LMP1-expressing cells
(Figure 5A,B). Fatostatin and luteolin treatment reduced
lipogenesis of NP69-pLNSX cells by 35–70%, whereas
a 54–87% reduction was observed in NP69-LMP1
cells (Figure 5A). Similarly, fatostatin and luteolin
reduced lipogenesis in HK1-pLNSX cells by 28–46%
and in HK1-LMP1 cells by 50–69% (Figure 5B).
Western blot analysis confirmed that both luteolin and
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Figure 3. LMP1 activation of the mTOR signaling pathway is required for SREBP1-mediated lipogenesis. (A) NP69-pLNSX and NP69-LMP1
cells treated with vehicle alone (Blank), Torin 1 (0.3 μM) or Torin 2 (0.1 μM). (B) NP69 cells transfected with either control pCDNA3 vector or
pCDNA3-LMP1 expression vector, together with a control scrambled siRNA (siCtl), or siRNA specific for Raptor (siRaptor), Rictor (siRictor),
or mTOR (simTOR), were subjected to western blotting analysis for the indicated proteins. (C) NP69-pLNSX and NP69-LMP1 cells transfected
with the indicated siRNAs for 24 h were subjected to lipid synthesis measurements. The asterisks indicate a significant difference (*p< 0.05,
**p< 0.01, ***p< 0.001).
fatostatin effectively inhibited SREBP1 maturation and
FASN expression in NP69-LMP1 and HK1-LMP1 cells
(supplementary material, Figure S2).
To determine whether lipogenesis conferred a growth
advantage to LMP1-expressing cells, pLNSX control
and LMP1-expressing NP69 and HK-1 cells were
grown in culture medium supplemented with 1% serum
together with increasing doses of luteolin or fatostatin
for 1–4 days, and the effects on cell growth were exam-
ined. As shown in Figure 5D–G, inhibition of fatty
acid synthesis by luteolin or fatostatin reduced the pro-
liferation of both control and LMP1-expressing cells,
although NP69-LMP1 and HK1-LMP1 cells appeared
to be more susceptible to the actions of both drugs.
The IC50 values of luteolin at day 3 in NP69-pLNSX,
NP69-LMP1, HK1-pLNSX and HK1-LMP1 cells were
2.6, 1.14, 12.4 and 5.6 μM, respectively. Similarly, the
IC50 values of fatostatin at day 3 in NP69-pLNSX,
NP69-LMP1, HK1-pLNSX and HK1-LMP1 cells
were 6.5, 2.9, 5.6 and 3.3 μM, respectively. Also, these
two inhibitors suppressed lipogenesis in C666-1 NPC
cells by 50% (Figure 5C) and inhibited their prolifer-
ation; the IC50 values of luteolin and fatostatin at day
4 were 9.6 and 25.5 μM, respectively (Figure 5H,I).
These findings indicate that suppression of lipogenesis
inhibits LMP1-induced proliferation in both malignant
and non-malignant nasopharyngeal epithelial cells,
implying that the induction of lipogenesis by LMP1 is
an essential mechanism in facilitating cell proliferation.
Inhibitors of lipogenesis suppress NPC growth
and induce apoptosis in vivo
Next, we examined whether blocking lipogenesis
inhibited the growth of NPC tumors in vivo. C666-1
cells were subcutaneously injected into the flanks of
nude mice. When tumors reached 50mm3 in size, the
mice were injected intraperitoneally with PBS, luteolin
(20mg/kg) or fatostatin (15mg/kg) every 2–3 days
for 19 days. Body weight and tumor size were mea-
sured every several days. At the endpoint, mice were
killed and tumors were harvested. Both luteolin and
fatostatin significantly inhibited tumor growth in mice
(p< 0.0001) (Figure 6A). In mice treated with lute-
olin or fatostatin, substantially lower tumor weights
and smaller tumor sizes were observed (p< 0.0001)
(Figure 6B,C). Surprisingly, no noticeable weight loss
was observed in mice treated with either drug (supple-
mentary material, Figure S3). Immunohistochemical
staining analysis of NPC tumors from these two groups
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Figure 4. Elevation of FASN expression correlates with LMP1 expression in NPC tumors and is associated with poor prognosis in NPC patients.
(A) Immunohistochemical staining of FASN and LMP1 in primary NPC and normal nasopharyngeal epithelium (NE) specimens. An absence
of FASN and LMP1 expression was observed in NE (N1). In NPC tumor T4, which is LMP1-negative, low levels of FASN (immunoreactivity
score of 1) were observed. In NPC tumors T13, T22, and T34, which are LMP1-positive, moderate (immunoreactivity score of 4) and high
(immunoreactivity scores of 6 and 8) levels of FASN were observed. Yellow arrow: normal nasopharyngeal epithelium. Red arrow: NPC tumor
cells. (B) Dot plot showing the immunoreactivity scores of FASN staining within the group of tumors with and without LMP1 expression
(N = 38). All LMP1-positive NPC tumors (13/13) showed strong FASN expression (immunoreactivity score of ≥3). The median value of each
group is shown by the horizontal line. The p-value between two groups is shown. (C) Kaplan–Meier survival curves for NPC patients with
available follow-up information. High FASN expression: immunoreactivity score of ≥3, n= 16. Low FASN expression: immunoreactivity
score of <3, n= 7.
of mice indicated that both luteolin and fatostatin
effectively inhibited FASN expression (Figure 6D;
supplementary material, Figure S4). In addition, histo-
logical investigations of tumor tissues revealed more
pronounced necrosis in both the luteolin-treated (35%)
and fatostatin-treated (43%) groups than in the con-
trol (5%) group (Figure 6D). An examination of cell
proliferation by immunohistochemical staining for
Ki67, and apoptosis by staining for cleaved caspase-3
(CC3), revealed that both drugs significantly inhib-
ited cell proliferation and increased apoptosis. As
shown in Figure 6D, the percentages of Ki67-positive
cells were markedly lower in the tumor tissues of the
luteolin-treated (56%) and fatostatin-treatyed (45%)
groups than in the control group (70%). Also, the per-
centages of CC3-positive cells were significantly higher
in the luteolin-treated (36%) and fatostatin-treated
(31%) treated groups than in the control group (12%).
Western blotting analysis provided further evidence for
the induction of CC3 and cleaved poly(ADP-ribose)
polymerase in luteolin-treated and fatostatin-treated
tumors (supplementary material, Figure S4). These
findings indicate that inhibition of lipogenesis by lute-
olin and fatostatin causes cell apoptosis and necrosis,
leading to tumor growth suppression.
Discussion
The oncogenic LMP1 protein is frequently found to
be expressed in NPC tumors. As well as promoting
cell growth, transformation, invasion, and migra-
tion, LMP1 also plays a role in modulating host cell
metabolic pathways [1,3,26]. In previous studies, we
have demonstrated an ability of LMP1 to promote
aerobic glycolysis through constitutive activation of
the fibroblast growth factor 2–fibroblast growth fac-
tor receptor 1 signaling pathway and upregulation
of c-Myc and hypoxia-inducible factor (HIF) 1α,
which are two primary regulators of aerobic gly-
colysis [5]. LMP1 also inactivates liver kinase B1
(LKB1)–5′-AMP-activated protein kinase (AMPK)
to promote proliferation and anchorage-independent
growth [4]. Here, we report a novel function of LMP1 in
promoting SREBP1-mediated de novo lipogenesis, an
effect that facilitates cell growth and tumor development
(supplementary material, Figure S5).
In this study, we show that LMP1 increases SREBP1
expression and activity in nasopharyngeal epithe-
lial cells. Luciferase promoter reporter assays and
RT-qPCR analysis demonstrate that LMP1 upregulates
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 246: 180–190
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Figure 5. LMP1 induction of lipogenesis contributes to cell proliferation. (A–C) NP69-pLNSX and NP69-LMP1 cells (A), HK1-pLNSX and
HK1-LMP1 cells (B) and C6661-1 EBV-positive NPC cells (C) cultured with 1% serum were treated with dimethylsulfoxide (DMSO) (vehicle),
luteolin (20 μM) or fatostatin (15 μM) for 16 h prior to lipogenesis measurements. Relative lipogenesis was calculated with vehicle-treated
cells as the reference control (set at 1). (D–I) NP69-pLNSX and NP69-LMP1 cells (D and E), HK1-pLNSX and HK1-LMP1 cells (F and G) and
C666-1 cells (H and I) were treated with increasing doses of inhibitors, as indicated, for 3 days prior to cell growth analysis. Relative cell
growth was calculated with vehicle-treated cells as the reference control (set at 1). ***p< 0.001.
SREBP1 at the transcriptional level (Figure 1A,B),
and western blotting analysis demonstrates that LMP1
promotes SREBP1 maturation and the expression of
its downstream target FASN (Figure 1C,D). Using a
[14C]acetate incorporation assay, we demonstrate the
ability of LMP1 to promote lipogenesis (Figure 1F).
Interestingly, silencing LMP1 in EBV-infected NPC
cells resulted in a reduction in FASN expression and
lipogenesis (Figure 2C,D). Furthermore, suppress-
ing lipogenesis with inhibitors significantly reduced
LMP1-induced proliferation (Figure 5). Collectively,
these findings demonstrate that LMP1 induction of
lipogenesis in NPC contributes to cell proliferation.
SREBPs tightly regulate lipogenesis. However, the
mechanism underlying the expression and activity of
SREBPs is still unclear. Hypoxia, glucose and insulin
have been found to increase the expression of SREBPs
[10]. Interestingly, we and others have reported a
function of LMP1 in promoting HIF-1 expression
and glucose uptake [5,26]. mTORC1 and mTORC2
have been shown to regulate SREBP activity and
lipogenesis through multiple inputs [27–30]. Here, in
line with other studies [18–20], we demonstrate that
LMP1 increases the phosphorylation of 4E-BP1 and
p70S6K, which are two established targets of mTOR,
in nasopharyngeal epithelial cells (Figures 1–3). Using
siRNA targeting raptor or rictor, we show that both
the mTORC1 and mTORC2 signaling pathways are
involved in LMP1-mediated lipogenesis (Figure 3).
The mTOR signaling pathway is complicated, as it
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Figure 6. Suppression of NPC tumor growth by inhibitors of lipogenesis. Mice bearing C666-1 xenografts were treated with PBS (control),
luteolin (20mg/kg) or fatostatin (15mg/kg) every 2–3 days for 3weeks. (A) Tumor size was measured every 2–3 days for 19 days. (B and
C) At the endpoint, mice were killed, and tumors were (B) weighed and (C) photographed. (D, left panel) The harvested xenografts were
embedded for hematoxylin and eosin (H&E) staining and immunohistochemical staining analysis. (D, right panel) The percentage of necrosis,
and positive staining for FASN, Ki67, and CC3, were measured, and are shown as dot-plots. Lines and bars are mean and standard error of
the mean of each experimental group. *p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001.
contains both positive and negative feedback loops,
and its downstream signaling interconnects with other
cell growth and survival pathways [28–31]. mTORC2
is activated by ribosomes and PI3K signaling, and is
negatively regulated by an mTORC1-induced p70S6
kinase, which dampens PI3K signaling by inhibiting
insulin receptor substrate 1 [28–31]. mTORC1 activity
is induced by the PI3K–AKT, Ras–ERK–MAPK,
IKKα–nuclear factor-αB (NF-αB) and IKKβ–NF-αB
pathways, all of which inhibit tuberous sclerosis
complex (TSC), a critical negative regulator of
mTORC1. mTORC2-induced AKT signaling also
activates mTORC1. In contrast, LKB1–AMPK inhibits
mTORC1 by activating TSC2 and inactivating raptor
[28–31]. Interestingly, AMPK is an inhibitory target of
LMP1 [4]. PI3K–AKT, Ras–ERK–MAPK and NF-κB
are three major pathways engaged by LMP1 [2;3].
Thus, LMP1 induction of mTOR–SREBP-induced
lipogenesis appears to be mediated through multiple
downstream targets and/or signaling pathways.
Overexpression of FASN has been documented in
oral hairy leukoplakia, an EBV-associated benign lesion
associated with robust EBV lytic replication [32]. FASN
is induced by the EBV-encoded lytic protein BRLF-1
through the p38-MAPK pathway, and is required for
lytic viral gene expression [32]. Similarly, hepatitis
B virus and hepatitis C virus lytic infection in liver
cancer cells is associated with the induction of fatty acid
synthesis for the formation of viral envelopes [33–35].
Another γ-herpesvirus, Kaposi’s sarcoma-associated
herpesvirus, has been shown to induce FASN expres-
sion and fatty acid synthesis for the survival of latently
infected PEL cells [36]. Here, we found higher lev-
els of SREBP1 activation and FASN expression in
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EBV latently infected NPC cells and xenografts, in
which LMP1 was expressed (Figure 2). Whereas nor-
mal nasopharyngeal epithelium showed an absence of
expression of FASN and LMP1 (Figure 4A), a high
level of FASN expression in NPC primary tumors
was common, and correlated significantly with LMP1
expression (Figure 4A,B). In line with previous studies,
elevated FASN expression was significantly associated
with T3–T4 stage primary tumors, N1–N3 lymph
node metastasis and poor overall survival of NPC
patients (Figure 4C; supplementary material, Table S1)
[37]. These findings suggest that LMP1 induction of
FASN and lipogenesis is involved in NPC progression.
Among the LMP1-negative NPC tumors examined,
nine of 25 (36%) showed a moderate or high level of
FASN expression (Figure 4B). Our previous genetic
analyses indicated that somatic mutations and/or aber-
rant expression of signaling proteins (lymphotoxin β
receptor, PIK3CA, p50, RelB, Bcl3, epidermal growth
factor receptor, and RAS) or signaling regulators
(INPP4B, TRAF3, TRAF2, A20, NFKBIA, TNFAIP3,
and CYLD) are common in NPC, resulting in constitu-
tive activation of the ERK1/2, NF-κB and PI3K–AKT
pathways [38–40]. Therefore, the genetic background
of NPC tumors, in addition to LMP1 expression, is
likely to contribute to FASN upregulation.
Given that FASN expression is commonly increased
in virus-associated cancers, lipogenesis appears to be
essential for viral infection and cancer progression
[35]. As lipogenesis is not common in normal cells,
targeting lipogenesis (or lipogenic pathways) might
selectively inhibit the growth of virus-infected cells and
of highly proliferative cancer cells in the early stage
of cancer development. In this study, we examined the
effects of fatostatin and luteolin on cell growth and
tumor development in relation to NPC. Fatostatin is
a small molecule that specifically blocks proteolytic
activation of SREBPs [24]. Luteolin is a plant flavonoid
that has inhibitory effects on lipogenesis [23]. Both
fatostatin and luteolin significantly inhibit SREBP1
activity, lipid synthesis and cell proliferation induced by
LMP1 (Figure 5; supplementary material, Figure S2).
Interestingly, luteolin has been reported to inhibit the
signaling activities of the PI3K–AKT, MAPK–ERK
and mTOR pathways [41], which are the major path-
ways required for SREBP-mediated lipogenesis by
LMP1. Moreover, fatostatin and luteolin significantly
inhibit the proliferation and tumorigenic growth of
C666-1 cells. In nude mice, fatostatin and luteolin at a
doses that effectively downregulate FASN expression
caused a marked reduction in tumor growth (Figure 6;
supplementary material, Figure S4). Surprisingly, no
significant weight loss was observed in mice treated
with luteolin or fatostatin (supplementary material,
Figure S3). The promising effects of these inhibitors in
suppressing NPC tumor growth with low-level toxicity
suggest possible clinical utility for the treatment of
NPC. Luteolin is a dietary flavonoid found in vegeta-
bles, fruits, and herbs. In addition to its inhibitory effect
on lipogenesis, luteolin suppresses inflammation, angio-
genesis, cell proliferation, and metastasis, all of which
are associated with cancer development [41]. Interest-
ingly, luteolin has been shown to induce G1 arrest and
inhibit EBV reactivation in NPC cells [42,43]. Given
that luteolin is a natural polyphenolic compound with
low toxicity, it may prove to be a promising compound
for the inhibition of EBV infection and the treatment of
EBV-associated cancers. The potential of luteolin for
the treatment of EBV-associated malignancies is worthy
of further evaluation, particularly in clinical trials.
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